Altre lingue Crescita Therapeutics Inc.

Azioni

CTX

CA2258471028

Mercato chiuso - Toronto S.E. Altri mercati azionari 21:59:47 26/04/2024			Variaz. 5gg	Var. 1 gen.
0,43 ^CAD	0,00%		-1,15%	-12,24%

13/03	Crescita Therapeutics riporta una perdita netta Q4 di 0,01 dollari per azione	MT
13/03	Crescita Therapeutics Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Crescita Therapeutics Reports Q4 Net Loss of $0.01 Per Share	13/03
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.	13/03
Crescita Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Crescita Therapeutics Brief: Q4 EPS Basic and Diluted Loss $0.01	13/03
Crescita Reports Q4 and Fiscal 2023 Results	13/03
Crescita Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/03
North American Morning Briefing : Stock Futures -2-	13/03
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.	08/11
Crescita Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Crescita Reports Third Quarter 2023 Results	08/11
Crescita Therapeutics Obtains TSX Approval for Normal Course Issuer Bid	29/08/23
Crescita Therapeutics Brief: Announced Approval of Normal Course Issuer Bid	29/08/23
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid	29/08/23
Crescita Therapeutics Inc. announces an Equity Buyback for 1,821,616 shares, representing 8.94% of its issued share capital.	29/08/23
Crescita Therapeutics Inc. authorizes a Buyback Plan.	29/08/23
- Crescita Therapeutics Brief: Q2 Revenue $5.162 Million; Ending cash was $10,226, down $49 for the quarter	09/08/23
Crescita Reports Second Quarter 2023 Results	09/08/23
Crescita Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders	21/06/23
Crescita Therapeutics Inc. Announces Launch of Topical Anaesthetic Pliaglis(R) in Europe in Its European Core Markets Including Germany, the United Kingdom and Ireland	01/06/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Crescita Therapeutics Inc.

Azioni

CTX

CA2258471028

Altre lingue

Filtri